Companies › Vedanta Biosciences
1 active drug program in 1 registered trial: 1 Phase 3; Infectious disease; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VE303 Live biotherapeutic product consisting of 8 clonally derived, nonpathogenic, nontoxigenic, | – | Phase 3 | Clostridium Difficile | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06237452 | VE303 | Phase 3 | Clostridium Difficile | Infectious disease | Jun 2027 |
No annotated target.
–
Chengdu CoenBiotech Biofabri Novavax Valneva Austria Green Cross
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.